| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 03/12/2024 | 14:05 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:GALT | Galectin Therapeutics Inc |
| 03/12/2024 | 14:04 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:GALT | Galectin Therapeutics Inc |
| 03/12/2024 | 14:03 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:GALT | Galectin Therapeutics Inc |
| 14/11/2024 | 14:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:GALT | Galectin Therapeutics Inc |
| 14/11/2024 | 13:51 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:GALT | Galectin Therapeutics Inc |
| 23/10/2024 | 19:39 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 04/10/2024 | 22:10 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 05/08/2024 | 14:38 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 23/07/2024 | 15:43 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:GALT | Galectin Therapeutics Inc |
| 01/12/2023 | 22:50 | Edgar (US Regulatory) | Form 5 - Annual statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 01/12/2023 | 22:38 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:GALT | Galectin Therapeutics Inc |
| 13/11/2023 | 15:21 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:GALT | Galectin Therapeutics Inc |
| 13/11/2023 | 14:45 | GlobeNewswire Inc. | UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update | NASDAQ:GALT | Galectin Therapeutics Inc |
| 13/11/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update | NASDAQ:GALT | Galectin Therapeutics Inc |
| 03/11/2023 | 13:00 | GlobeNewswire Inc. | Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD | NASDAQ:GALT | Galectin Therapeutics Inc |
| 23/10/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 12/10/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors | NASDAQ:GALT | Galectin Therapeutics Inc |
| 03/10/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver | NASDAQ:GALT | Galectin Therapeutics Inc |
| 26/09/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 11/09/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 07/09/2023 | 18:00 | GlobeNewswire Inc. | Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 14/08/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update | NASDAQ:GALT | Galectin Therapeutics Inc |
| 16/06/2023 | 13:51 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GALT | Galectin Therapeutics Inc |
| 15/05/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update | NASDAQ:GALT | Galectin Therapeutics Inc |
| 15/05/2023 | 13:56 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:GALT | Galectin Therapeutics Inc |
| 27/04/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 25/04/2023 | 12:06 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:GALT | Galectin Therapeutics Inc |
| 18/04/2023 | 14:00 | GlobeNewswire Inc. | Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases | NASDAQ:GALT | Galectin Therapeutics Inc |
| 14/04/2023 | 23:27 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) | NASDAQ:GALT | Galectin Therapeutics Inc |
| 30/03/2023 | 22:01 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:GALT | Galectin Therapeutics Inc |